CMXI Stock News Cytomedix Inc. New (CMXI) 0.3901 07/26/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cytomedix Inc. New (CMXI) 0.3901 $CMXI

Malignant Glioma - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ljjnrf/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Malignant Glioma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - ZIOPHARM Oncology, Inc. - Cytomedix, Inc. - Stemline Therapeutics, Inc. - EirGen Pharma Ltd. For more information visit http://www.researchandmarkets.com/research/lj...ant_glioma

Cytomedix receives USD26m from second tranche under its convertible debt financing
M2 - Fri Jun 27, 4:54AM CDT
Regenerative therapies company Cytomedix (Other OTC:CMXI) said on Thursday that it has closed the second tranche for gross proceeds of USD26m under its convertible debt financing with certain investment funds managed by Deerfield Management Company.

Cytomedix Completes the Second Tranche of the $35 Million Convertible Debt Financing With Deerfield Management Company
GlobeNewswire - Thu Jun 26, 7:14AM CDT
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, today announced receipt, following satisfaction of closing conditions, of the second tranche of the gross proceeds in the amount of $26 million (for a total $35 million) in convertible debt financing from certain investment funds managed by Deerfield Management Company, L.P. Under the terms of the Facility Agreement dated as of March 31, 2014, Deerfield agreed to provide to the Company up to $35 million in financing through a senior secured convertible debt facility. The commitment consisted of two separate tranches, of which the first $9 million was received upon initial closing of the transaction on March 31, 2014. The second tranche in the gross amount of $26 million was completed as anticipated. As previously disclosed, the notes have a fixed conversion price of $0.52 per share. Following the retirement of debt and payment of certain expenses associated with the closing of the second tranche, the net proceeds to the Company were approximately $22.1 million.

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014
M2 - Tue Jun 24, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rtp9gn/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - AstraZeneca PLC - Athersys, Inc. - CardioVascular BioTherapeutics, Inc. - Sigma-Tau S.p.A. - Celgene Corporation - Cytokinetics, Incorporated - Cytomedix, Inc. - ReNeuron Group plc - Genovate Biotechnology Co., LTD. - Proteon Therapeutics, Inc. - Diffusion Pharmaceuticals LLC - Theravasc, Inc. - ViroMed Co., Ltd. - DNAVEC Corporation - miRagen Therapeutics, Inc. - RegenoCELL Therapeutics, Inc. - Provasculon, Inc. - Multi Gene Vascular Systems Ltd - Cardiolynx AG - Exodos Life Science Limited - Recardio GmbH For more information visit http://www.researchandmarkets.com/research/rtp9gn/peripheral

Cytomedix, Inc. - Product Pipeline Review - 2014
PR Newswire - Tue Jun 17, 3:44PM CDT
Reportbuyer.com has added a new market research report:

Global Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Clinical Trials Report 2014
M2 - Fri Jun 06, 4:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bnrww/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Global Clinical Trials Review, H1, 2014" report to their offering. Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Global Clinical Trials Review, H1, 2014 includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Shire Plc - UniQure NV - Lysogene - Synageva BioPharma Corp. - Cytomedix, Inc. - BioMarin Pharmaceutical Inc. - Academic Medical Center - Masonic Cancer Center - The University of Manchester - The University of Chicago - Hospices Civils de Lyon - University of Louisville - University of Minnesota For more information visit http://www.researchandmarkets.com/research/2b...saccharido

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Cytomedix, Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Tue Jun 03, 12:26PM CDT
Levi & Korsinsky, LLP is investigating Cytomedix, Inc. (OTC MKTS: CMXI) in connection with possible claims of breaches of fiduciary duty by members of the Board of Directors of the Company.

Cytomedix Reports 2014 First Quarter Financial Results
GlobeNewswire - Thu May 15, 3:22PM CDT
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, today reported financial results for the three months ended March 31, 2014.

Deerfield Announces a $35 Million Dollar Investment Commitment to Cytomedix, Inc.
Business Wire - Mon Mar 31, 3:45PM CDT
Deerfield Management Company announced today that it has committed to invest up to $35 million dollars in Cytomedix, Inc. (OTCQX: CMXI) through a senior secured convertible debt facility with warrants.

Cytomedix Announces Senior Management Appointments
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Industry Veteran and Wound Care Commercial Expert Dean Tozer Appointed as Executive Vice President and Chief Commercial Officer

Cytomedix Reports 2013 Fourth Quarter and Full Year Financial Results; Announces Up to $35 Million Convertible Debt Financing With Deerfield Management Company
GlobeNewswire - Mon Mar 31, 3:37PM CDT
$2 Million Additional Equity Investment with Anson Group

Cytomedix to Host Fourth Quarter & Fiscal Year End 2013 Financial Results Conference Call on Tuesday, April 1, 2014
GlobeNewswire - Tue Mar 25, 7:17AM CDT
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, announced today that it will release financial results for the three- and twelve-month period ended December 31, 2013, after the close of the market on Monday, March 31, 2014.

Yale prepares for atom smasher's farewell, sets stage for new physics era
M2 - Tue Feb 25, 8:45AM CST


Malignant Glioma - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/zr3vfj/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2013" report to their offering. 'Malignant Glioma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. Scope - A snapshot of the global therapeutic scenario for Malignant Glioma. - A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malignant Glioma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Malignant Glioma Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Drug Profiles Eir-060 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile Carboxyamidotriazole Orotate - Drug Profile SL-701 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile SAR-245409 - Drug Profile WT1 Peptide Vaccine - Drug Profile celecoxib Dendritic Cell Vaccine [temozolomide] Radiation Therapy - Drug Profile Dendritic Cell Vaccine - Drug Profile Peptide Vaccine [sargramostim] - Drug Profile ALD-451 - Drug Profile First Generation Attenuated Strain Of Reovirus - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Sanofi Cytomedix, Inc. Stemline Therapeutics, Inc. EirGen Pharma Ltd. Tactical Therapeutics, Inc For more information visit http://www.researchandmarkets.com/research/zr...ant_glioma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

W2 Energy Reports on 2013 and Looks Forward to 2014
Marketwire - Tue Jan 14, 1:06PM CST
W2 Energy, Inc. (OTC Pink: WTWO) is pleased to report on 2013's past year progress and looking forward into 2014.

Better Increase, Best Family, Fun Day for Eskom Workers [press release]
All Africa Global Media - Tue Jan 14, 12:38PM CST
The National Union of Mineworkers (NUM) is extremely saddened by Eskom for its failure to pay the salary increase of its employees "who have been unilaterally declared essential service by Eskom Management".

Cytomedix Announces Completion of RECOVER-Stroke Trial Enrollment and Update on Bright Cell Technology
Marketwire - Mon Jan 06, 7:02AM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, announced today the completed enrollment of the RECOVER-Stroke trial. Based on an interim resizing analysis that was performed on the existing population of all subjects who have reached the treatment plus 90 days primary efficacy endpoint, it was concluded that the ongoing RECOVER-Stroke trial is adequately powered based on pre-specified assumptions at the current enrollment of 48 patients. Consequently, additional screening and enrollment of new patient subjects will cease immediately. The Company expects to announce the top line clinical results in May 2014 when they become available.

Cytomedix Provides Update on Reimbursement Progress for AutoloGel(TM) in the Hospital Outpatient Prospective Payment System (HOPPS)
Marketwire - Wed Sep 18, 7:01AM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet technologies, today provided an update on recent progress in attaining appropriate reimbursement for AutoloGel(TM) in the Medicare Hospital Outpatient Prospective Payment System (HOPPS). The Company has filed public comments with the Centers for Medicare and Medicaid Services (CMS) on the previously announced proposed rules for HOPPS and recently held a direct meeting with CMS. Based on these interactions, Cytomedix believes that CMS now has all the information required to make a final and fully informed decision on AutoloGel reimbursement in the hospital outpatient setting.

Cytomedix Announces Strategic Reorganization of Research and Development Operations
Marketwire - Tue Sep 17, 3:01PM CDT
Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative cell based technologies, today announced that, in line with its strategy to build a profitable and successful company commercially focused on the wound care market, it will reorganize its research and development activities. As part of this initiative, the Company's ongoing financial support of the current RECOVER-Stroke trial and the underlying ALDH Bright Cell technology will be substantially concluded as of year-end 2013. The Company is exploring a range of strategic options for continuing its clinical programs beyond year-end 2013, which options may include, among others, technology transfer, spinout, licensing or other similar transactions involving the underlying technology.

OTC Daily Alert Stock Watch - Cytomedix, Inc (OTCQX: CMXI)
WorldStockWire - Fri Aug 16, 5:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Central Florida Buyers Face the Cash Reality First

Updated Category News Views 94

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 24

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 53

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 103

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Minnesota Giving Record Signals a Stressed Safety Net

Updated Category News Views 63

Thirty-eight million dollars landing in one day is no small civic heartbeat. Minnesota’s Give to the Max Day brought in a record $38.4 million in 2026 for nearly 6,000 nonprofits and schools, edging past the $37.8 million raised in 2025. More than 65,000 people gave. That deserves a clear-eyed nod, not a cynical shrug. Still, the number carries two messages at once. It...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 36

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 18

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Soitec's Current Share Capital and Voting Rights

Updated Category News Views 82

Understanding Soitec's Share Capital and Voting Rights For stakeholders in the corporate sector, grasping the concepts of share capital and voting rights is essential. Soitec, a prominent player in the semiconductor materials industry, has made notable strides and contributions in this field. Let’s explore the most recent updates regarding the total number of voting...

Continue Reading
Investing in Tomorrow: Why Future Industries Matter Today

Updated Category News Views 202

The Importance of Investing in Future Industries Many people today ponder the importance of investing in future industries, questioning why resources should be allocated to them when they seem distant from our everyday lives. This inquiry addresses a crucial topic with significant long-term implications. Future industries like quantum technology, nuclear fusion energy,...

Continue Reading
TIER IV Partners with JR Central to Transform Regional Mobility

Updated Category News Views 184

TIER IV and JR Central: A Partnership for the Future TIER IV, a leader in open-source software for autonomous driving, is embarking on an exciting journey by forming a strategic partnership with Central Japan Railway Company (JR Central). This collaboration aims to revolutionize regional transportation by integrating cutting-edge autonomous driving technology with rail...

Continue Reading
eMazzanti Technologies Shines with Four Microsoft Designations

Updated Category News Views 186

eMazzanti Technologies Celebrates Major Microsoft Partnership Success A Remarkable Achievement in the Tech Landscape eMazzanti Technologies, a well-regarded provider of IT services and cybersecurity solutions, proudly announces its attainment of four distinguished Solutions Partner designations in the Microsoft AI Cloud Partner Program. This accomplishment elevates the...

Continue Reading
Understanding the Current Trends in Wynn Resorts' Options Market

Updated Category News Views 200

Understanding Wynn Resorts' Trading Dynamics In a remarkable turn of events, significant investors have adopted a bullish outlook on Wynn Resorts WYNN. This new sentiment has implications for retail traders and analysts trying to gauge the company's future performance. Investor Sentiment: A Deep Dive Ricocheting through financial markets, the latest trades signaling...

Continue Reading